Cargando…

Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India

PURPOSE: Osteonecrosis of the jaw (ONJ) is a rare but complicated side effect of antiresorptive medications. The aim of the study is to evaluate the dental and drug-related factors related to ONJ among patients on these drugs at a tertiary cancer center, India. METHODOLOGY: A retrospective record re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sankar, Pramod S, Thilak, SA, Nayak, P, Tripathy, JP, Satheesan, B, Rajitha, AV
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863406/
https://www.ncbi.nlm.nih.gov/pubmed/29599581
http://dx.doi.org/10.4103/ccd.ccd_696_17
_version_ 1783308382215602176
author Sankar, Pramod S
Thilak, SA
Nayak, P
Tripathy, JP
Satheesan, B
Rajitha, AV
author_facet Sankar, Pramod S
Thilak, SA
Nayak, P
Tripathy, JP
Satheesan, B
Rajitha, AV
author_sort Sankar, Pramod S
collection PubMed
description PURPOSE: Osteonecrosis of the jaw (ONJ) is a rare but complicated side effect of antiresorptive medications. The aim of the study is to evaluate the dental and drug-related factors related to ONJ among patients on these drugs at a tertiary cancer center, India. METHODOLOGY: A retrospective record review of patients who received antiresorptive medication at our center from 2011 to 2014 was done. The demographic factors, type, dosage, and duration of the medication and dental history were collected, and the data were entered an analyzed using Epidata software. RESULTS: A higher incidence of ONJ (8.1%) was noted in our sample (n = 183). Dental intervention after zoledronic acid (ZA) administration showed a statistical significance (P < 0.001). No significance (P value) was noted with respect to sex (0.78), age (0.28), median duration (0.9), and median dosage (0.9) of ZA. CONCLUSION: Oro-dental screening and dental monitoring shall reduce the incidence of ONJ. Within the limitations of our study, no significant relation could be pointed toward the dosage and duration of the drug and development of ONJ.
format Online
Article
Text
id pubmed-5863406
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-58634062018-03-29 Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India Sankar, Pramod S Thilak, SA Nayak, P Tripathy, JP Satheesan, B Rajitha, AV Contemp Clin Dent Original Article PURPOSE: Osteonecrosis of the jaw (ONJ) is a rare but complicated side effect of antiresorptive medications. The aim of the study is to evaluate the dental and drug-related factors related to ONJ among patients on these drugs at a tertiary cancer center, India. METHODOLOGY: A retrospective record review of patients who received antiresorptive medication at our center from 2011 to 2014 was done. The demographic factors, type, dosage, and duration of the medication and dental history were collected, and the data were entered an analyzed using Epidata software. RESULTS: A higher incidence of ONJ (8.1%) was noted in our sample (n = 183). Dental intervention after zoledronic acid (ZA) administration showed a statistical significance (P < 0.001). No significance (P value) was noted with respect to sex (0.78), age (0.28), median duration (0.9), and median dosage (0.9) of ZA. CONCLUSION: Oro-dental screening and dental monitoring shall reduce the incidence of ONJ. Within the limitations of our study, no significant relation could be pointed toward the dosage and duration of the drug and development of ONJ. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5863406/ /pubmed/29599581 http://dx.doi.org/10.4103/ccd.ccd_696_17 Text en Copyright: © 2018 Contemporary Clinical Dentistry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sankar, Pramod S
Thilak, SA
Nayak, P
Tripathy, JP
Satheesan, B
Rajitha, AV
Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
title Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
title_full Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
title_fullStr Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
title_full_unstemmed Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
title_short Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India
title_sort osteonecrosis of the jaw among patients receiving antiresorptive medication: a 4-year retrospective study at a tertiary cancer center, kerala, india
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863406/
https://www.ncbi.nlm.nih.gov/pubmed/29599581
http://dx.doi.org/10.4103/ccd.ccd_696_17
work_keys_str_mv AT sankarpramods osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia
AT thilaksa osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia
AT nayakp osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia
AT tripathyjp osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia
AT satheesanb osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia
AT rajithaav osteonecrosisofthejawamongpatientsreceivingantiresorptivemedicationa4yearretrospectivestudyatatertiarycancercenterkeralaindia